UNSPSC 51412605: Floredil

This classification denotes a vasodilating agent with the molecular formula C16H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LHX2B2R19F, chemically known as 4-(2-(3,5-diethoxyphenoxy)ethyl)morpholine. but generally known as floredil, which bears US NIH Compound Identifier 216221. European Medicines Agency schedules Floredil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07650MIG.

UNSPSC 51412605 Floredil is a Commodity code covering pharmaceutical products — specifically, state and local governments are buying emergency medications, generic multi-source pharmaceuticals, and over-the-counter products through direct procurement, cooperative purchasing agreements, and exploratory vendor-relationship initiatives. The work includes supplying finished pharmaceutical inventory to fire rescue departments, health departments, correctional facilities, and state employee health plans, with vendors responsible for regulatory compliance (FDA, cGMP, DSCSA), expiration-date management, temperature-controlled logistics, and often Safety Data Sheets and accessibility documentation. Issuing bodies span city purchasing departments (Tampa Fire Rescue), state health agencies (Texas HHS Commission), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance / MMCAP), reflecting a mix of municipal emergency services, state Medicaid and employee health programs, and cross-jurisdictional procurement alliances that aggregate demand across participating states and localities.

Recent activity shows geographic concentration in the South and Upper Midwest. The City of Tampa issued Bid No. 26P00188 on April 24, 2026, seeking 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials for Tampa Fire Rescue, with bids due April 8, 2026, and an estimated contract value of $40,000 under a Small Local Business Enterprise sheltered-market designation. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026, and evaluated 75 percent on price competitiveness; vendors must maintain relationships with AmerisourceBergen, Cardinal Health, or Morris & Dickson and comply with cGMP and DSCSA. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capability information on direct-to-manufacturer prescription programs for self-insured state employee and retiree health plans, signaling future formal procurement once the state defines contracting specifications.